2 Monster Stocks to Double Up On Right Now Before They Rebound

Palantir and MercadoLibre have fallen 38% and 33% from their 52-week highs, respectively, but the article argues both still have strong long-term fundamentals. Palantir's revenue growth accelerated from 17% in 2023 to 29% and 56% in the following years, with analysts projecting 62% growth in 2026, while MercadoLibre posted 39% top-line growth last year despite margin pressure. The piece is primarily a valuation-and-quality argument rather than a new catalyst, so the near-term market impact should be limited.

Analysis

The key setup is not valuation compression but sentiment reset after two structurally strong compounders de-rated while fundamentals kept accelerating. That matters because crowded-growth names usually fall hardest when the market starts to doubt duration; here, the better read is that positioning is being washed out faster than the earnings runway is being impaired. If that’s right, the next move is less about multiple expansion immediately and more about a gap between buyable expectations and still-rising forward estimates.

Palantir is the cleaner tactical long because the business mix is shifting toward repeatable commercial demand, which should lower the market’s perceived dependence on episodic government wins. The second-order effect is that every incremental proof point in enterprise adoption can force a rapid re-rating: when a stock trades at a premium for “optionality,” the inflection comes when the market starts underestimating base-rate revenue persistence, not when it becomes cheap. The risk is that any slowdown in quarterly growth, even temporary, can hit the multiple hard over days to weeks because the stock is still priced like a near-perfect execution story.

MercadoLibre is more interesting as a medium-horizon recovery trade because the current margin pressure looks more like competitive investment than structural decay. Lower shipping thresholds and profit misses can persist for a few quarters, but that can still be bullish if it defends ecosystem share and monetization later; the market is likely extrapolating near-term compression too far into 2026. The hidden beneficiary is not just MELI itself but the broader Latin American fintech and logistics stack, where weaker rivals may not be able to match the cash burn needed to keep up.

The contrarian view is that this is a rare case where a pullback in quality growth is probably less about business deterioration and more about multiple indigestion. The tradeable edge is to focus on horizon mismatch: the market is pricing the next 1-2 quarters, while the businesses are compounding over 2-5 years. That creates attractive asymmetry for staggered entries, especially if you can tolerate volatility and avoid chasing into green days.

Key Decisions for Investors

• Initiate a staggered long PLTR position over the next 2-4 weeks; target a 6-12 month hold. Use the selloff to own accelerating forward revisions rather than wait for a cleaner valuation.
• Add MELI on further margin-related weakness, but size for a 3-6 month digestion period. Best risk/reward is after another miss or guide-down if the market over-penalizes near-term profitability.
• Pair trade: long PLTR / short NDAQ or another slower-growth software/market data compounder over the next quarter. Thesis is multiple re-rating for accelerating growth versus a lower-beta proxy facing less narrative upside.
• For higher-conviction risk control, buy PLTR calls with 6-9 months to expiry instead of stock if you expect a sharp sentiment reversal; the stock remains vulnerable to near-term multiple compression, so defined risk is preferable.
• If entering MELI, use scale-in with a stop on repeated downward gross margin revisions; the trade breaks if competitive intensity starts showing up in share loss rather than just temporary investment.